WP-1034, a novel Jak-Stat inhibitor, has proapoptotic and antileukemic activity in acute myeloid leukemia (AML) cell lines and AML patient samples.

被引：0
|
作者：
Faderl, S
Ferrajoli, A
Harris, D
Van, Q
Priebe, W
Estrov, Z
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[2] Univ Texas, MD Anderson Canc Ctr, Dept Dev Therapeut, Houston, TX 77030 USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2528
引用
收藏
页码：693A / 693A
页数：1
相关论文
共 32 条
  • [1] WP-10349 a novel Jak-Stat inhibitor, with proapoptotic and antileukemic activity in acute myeloid leukemia (AML)
    Faderl, S
    Ferrajoli, A
    Harris, D
    Van, Q
    Priebe, W
    Estrov, Z
    ANTICANCER RESEARCH, 2005, 25 (3B) : 1841 - 1850
  • [2] Proapoptotic effects of Deferasirox on acute myeloid leukemia (AML) cell lines
    Hinterleitner, C.
    Malenke, E.
    Bugl, S.
    Haap, M.
    Mueller, M. R.
    Heissnet, K.
    Kopp, H. -G
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 146 - 146
  • [3] Atiprimod blocks phosphorylation of JAK-STAT and inhibits proliferation of acute myeloid leukemia (AML) cells
    Faderl, Stefan
    Ferrajoli, Alessandra
    Harris, David
    Van, Quin
    Kantarjian, Hagop M.
    Estrov, Zeev
    LEUKEMIA RESEARCH, 2007, 31 (01) : 91 - 95
  • [4] WP-1066, a next-generation member of JAK-Stat inhibitors, induces cell cycle arrest, abrogates proliferation, and induces apoptosis of acute myeloid leukemia (AML) cells.
    Ferrajoli, A
    Faderl, S
    Van, Q
    Harris, DM
    Priebe, W
    Kantarjian, HM
    Talpaz, M
    Estrov, Z
    BLOOD, 2004, 104 (11) : 331A - 331A
  • [5] The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia
    Eriksson, A.
    Hermanson, M.
    Wickstrom, M.
    Lindhagen, E.
    Ekholm, C.
    Jensen, A. Jenmalm
    Lothgren, A.
    Lehmann, F.
    Larsson, R.
    Parrow, V.
    Hoglund, M.
    BLOOD CANCER JOURNAL, 2012, 2 : e81 - e81
  • [6] The novel tyrosine kinase inhibitor AKN-028 has significant antileukemic activity in cell lines and primary cultures of acute myeloid leukemia
    A Eriksson
    M Hermanson
    M Wickström
    E Lindhagen
    C Ekholm
    A Jenmalm Jensen
    A Löthgren
    F Lehmann
    R Larsson
    V Parrow
    M Höglund
    Blood Cancer Journal, 2012, 2 : e81 - e81
  • [7] The histone deacetylase inhibitor depsipeptide has differential activity in specific cytogenetic subsets of acute myeloid leukemia (AML)
    Odenike, OM
    Alkan, S
    Sher, D
    Godwin, JE
    Huo, DZ
    Myers, M
    Brandt, SJ
    Zhang, YM
    Vesole, DH
    Larson, RA
    Stock, W
    BLOOD, 2004, 104 (11) : 79A - 79A
  • [8] STI-8591, a Novel Tyrosine Kinase Inhibitor, Shows Excellent Antileukemic Activity in FLT3Mutated (mut) Acute Myeloid Leukemia (AML)
    Zhang, Yi
    Wei, Wenwen
    Zhang, Bin
    Sun, Jie
    Zhao, Dandan
    Chen, Fang
    Xu, Yongfang
    Qian, Yu
    Zhao, Yanchun
    Zhou, Yutong
    Xu, Wanhong
    Zhang, Xiaoying
    Mao, Long
    Marcucci, Guido
    Xu, Xiao
    Jin, Jie
    BLOOD, 2023, 142
  • [9] In Vivo Antileukemic Activity of Ost-01 in Acute Myeloid Leukemia (AML): A Novel Natural Product (NP) from Baccharis Coridifolia
    Kang, Hyunjun
    Hoang, Dinh Hoa
    Valerio, Melissa
    Pathak, Khyatiben V.
    Zhang, Lianjun
    Buettner, Ralf
    Chen, Fang
    Estrella, Katrina
    Graff, William
    Kuo, Ya-Huei
    Zhang, Bin
    Pirrotte, Patrick
    Nguyen, Le Xuan Truong
    Marcucci, Guido
    BLOOD, 2023, 142
  • [10] SGI-1776: A novel PIM kinase inhibitor with potent preclinical activity against Acute Myeloid Leukemia (AML)
    Swords, Ronan
    Kelly, Kevin
    Medina, Ernest
    Mahalingam, Devalingam
    Nawrocki, Steffan
    Bearss, David
    Ninomoto, Joi
    Berk, Gregory
    Giles, Francis
    Carew, Jennifer
    CANCER RESEARCH, 2009, 69
1234